Semaglutide Reduces Risk for MACE in Patients With Obesity and Heart Failure
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Aug. 28, 2024 -- Semaglutide reduces the risk for major adverse cardiovascular events (MACE) and composite heart failure end points compared with placebo in patients with overweight or obesity and heart failure, according to a study published online Aug. 24 in The Lancet.
John Deanfield, B.Chir., M.B., from the Institute of Cardiovascular Sciences at University College London, and colleagues examined whether semaglutide is beneficial for patients with atherosclerotic cardiovascular disease with a history of heart failure in a phase 3 trial conducted in 41 countries. The study included 17,604 patients (age, 45 years and older; body mass index, ≥27 kg/m2) who were randomly assigned to receive semaglutide or placebo (8,803 and 8,801 patients, respectively).
Overall, 24.3 percent of patients had a history of investigator-defined heart failure at enrollment: 53.0, 31.4, and 15.5 percent had heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, and unclassified heart failure, respectively. The researchers found that the incidence of clinical events was higher for patients with heart failure. All outcome measures (MACE, heart failure composite end point, cardiovascular death, and all-cause death) were improved with semaglutide for patients with versus without heart failure. In both the groups with heart failure with reduced ejection fraction and heart failure with preserved ejection fraction, semaglutide treatment resulted in improved outcomes in MACE and the composite heart failure end point.
"A large population of patients with atherosclerotic cardiovascular disease who have overweight or obesity and heart failure could benefit from semaglutide, without the need for previous detailed cardiovascular risk stratification," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Novo Nordisk, which manufactures semaglutide and funded the study.
Editorial (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted August 2024
Read this next
Real-World Weight Loss With Semaglutide, Tirzepatide Less Than That Seen in Clinical Trials
THURSDAY, June 12, 2025 -- For patients with obesity initiating pharmacotherapy with semaglutide or tirzepatide, weight loss at one year is 8.7 percent on average, which is lower...
Adherence to Healthy Diet Improves Cardiometabolic Risk, Even Without Weight Loss
WEDNESDAY, June 11, 2025 -- A healthy diet improves cardiometabolic risk factors, even if not associated with weight loss (WL), according to a study published online June 5...
Hyperinsulinemia Linked to Abnormal Uterine Bleeding
TUESDAY, June 10, 2025 -- In premenopausal women, hyperinsulinemia is associated with abnormal uterine bleeding (AUB), with body mass index (BMI) playing a role in this...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.